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Abstract 
We report the occurrence of chronic kidney disease after living-related kidney transplant 
involving monozygotic twin brothers of Afro-Caribbean origin who were both heterozygous 
for the G1 and G2 APOL1 kidney disease risk alleles. A 21 year-old black man with end-
stage kidney disease of unknown aetiology received a kidney from his monozygotic twin 
brother (confirmed by microsatellite analysis). Thirty months after transplantation, the patient 
presented proteinuria and decreased eGFR with typical focal segmental glomerulosclerosis 
lesions on the graft biopsy. He received steroid therapy, but progressed to kidney failure 5 
years later. The twin brother displayed normal kidney function without proteinuria at the time 
of transplant; however, 7 years later, he exhibited decreased estimated GFR (40 
ml/min/1.73m) and proteinuria (2.5 g/day). APOL1 genotyping of revealed that both donor 
and recipient were heterozygous for the G1 and G2 alleles. This unique case is in stark 
contrast to expectations for identical twin transplantation and suggests a role for APOL1 
polymorphisms in both the donor and recipient. 
 
Key words: APOL1 polymorphism, donor, kidney transplantation, outcome 
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Introduction 
 
The risk of non-diabetic chronic kidney disease (CKD) is 4-5 times higher for people of 
African ancestry than other groups1, 2. This was recently attributed to two sequence variants, 
G1 and G2, in the last exon of the APOL1 gene, encoding apolipoprotein L-1: these variants 
are common  in African Americans but absent from  people of European ancestry3. People 
with two risk alleles have an increased risk of focal and segmental glomerulosclerosis 
(FSGS), hypertension-related end-stage renal disease (ESRD), and HIV-associated 
nephropathy3-5. The ethnic origin of kidney transplantation recipients may influence the graft 
function outcome, and recipients with African ancestry are usually considered as at high risk 
of poor kidney outcome, although a French survey does not support this view6-9. The 
relationship between APOL1 risk variant alleles and allograft survival after kidney 
transplantation has been evaluated in two recent studies10, 11. The first study, with 2 years of 
post-transplant follow-up, showed that graft survival was significantly shorter in transplant 
recipients of donor kidneys with two APOL1 risk variant alleles11. By contrast, a retrospective 
study did not find that the 5-year post-transplant graft survival correlated with the APOL1 
genotype of the recipient10. Further investigations are required to clarify the consequences of 
both recipient and donor APOL1 genotype on the graft outcome after kidney transplantation.  
We describe here, for the first time, FSGS of the graft after a living-related kidney transplant 
and unsatisfactory kidney function outcome in the donor for a pair of monozygous twin 
brothers sharing the same APOL1 risk variant genotype. 
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Case report 
A 21-year-old man of Caribbean origin was referred to our Nephrology department in 2006 
for a first kidney transplantation. His medical history included ESRD of unknown origin 
requiring intermittent haemodialysis diagnosed one year before. No kidney biopsy was 
performed at the time of the first nephrological evaluation because kidney function was 
significantly abnormal (creatinine at 8.54 mg/dL, estimated glomerular filtration rate, (eGFR) 
was 10 ml/min/1.73m2 according to the 6-variable MDRD formula12) in a context of bilateral 
kidney atrophy. Nevertheless, initial clinical findings revealed high blood pressure (170/85 
mmHg) with significant proteinuria (3.4 g/day). There was no leucocyturia nor hematuria. 
The historical, immunological and viral screening including drug abuse, HIV serology, anti 
nuclear factor was negative. He underwent kidney transplantation with the left kidney from 
his identical twin brother. Twinship was confirmed by microsatellite analysis. At the time of 
kidney transplantation, the creatinine level for the donor twin was 1.18 mg/dL (eGFR: 100 
ml/min/1.73m2) without significant proteinuria (0.005 g/day). The donor had normal blood 
pressure. The pretransplant panel reactive antibody level was 0%. Immunosuppresive 
treatment consisted of steroid therapy exclusively: one pulse of methylprednisolone on two 
consecutive days then oral prednisone at 1 mg/kg/day progressively tapered and definitively 
stopped 15 days after surgical procedure. The post-transplantation course was unremarkable 
and kidney function on day 10 post-transplantation was optimal (creatinine 1.18 mg/dL, 
eGFR: 100 ml/min/1.73m²). Six months after transplantation, the patient presented with an 
increase of proteinuria (1.2 g/day) associated with severe hypertension requiring anti-
hypertensive therapy (amlodipine, irbesartan and hydrochlorothiazide). Kidney function 
remained unchanged and a biopsy was performed but was not informative. Thirty months 
after transplantation, he presented with significant decreased eGFR (creatinine 2.56 mg/dL, 
eGFR 43 ml/min/1.73m²) and persistent proteinuria (2.2 g/day). A second kidney biopsy 
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showed lesions typical of FSGS on three of 15 glomeruli analyzed (Figure 1A and 1B). The 
biopsy showed moderate interstitial fibrosis and tubular atrophy. Vessels appeared normal. 
Immunofluorescence study demonstrated segmental deposits of IgM and C3 in the areas of 
scarring. C4d immunostaining was negative. Our patient was treated with 1 mg/kg prednisone 
for 4 months for late recurrence of primary FSGS nephropathy on the graft. Unfortunately, 
kidney function declined progressively (Creatinine 12.27 mg/dL, eGFR 6 ml/min/1.73m²) 
with increase of proteinuria. No other treatment such as plasmapheresis or Rituximab was 
performed. Five years after transplantation, a third biopsy demonstrated extensive interstitial 
fibrosis (65% of total parenchyma) with severe glomerular involvement (70% of glomeruli 
obsolescent). The patient was prepared for chronic haemodialysis.  
Seven years after donation, the donor displayed significant proteinuria (2.53 g/day) without 
haematuria but associated with decreased eGFR (creatinine 2.5 mg/dL; and eGFR: 40 
ml/min/1.73m²) (Figure 2). We did not perform a kidney biopsy on the remaining kidney.  
The synchronous apparition of kidney disease may point toward a hereditary FSGS. As 
Lipska et al recently suggested13, we performed the sequencing of the integrality of podocin 
gene and did not identify any mutation. In the light of recent reports of genetic susceptibility 
associated with FSGS in people of African ancestry, we genotyped the APOL1 gene in both 
donor and recipient and both were heterozygous for the G1 and G2 APOL1 risk alleles 
(Figure 3).  
 
Discussion 
   We report here the first case of a decreased eGFR in both donor and recipient after 
living-related kidney transplantation involving twin brothers with APOL1 polymorphisms.   
This critical issue contrasts with the excellent expected outcome in a living donation between  
two monozygotic twins. A recent study clearly indicates that kidney allograft survival is 
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shorter in patients receiving deceased donor kidneys from African Americans with two 
APOL1 risk alleles than those receiving other kidneys11. Based on these findings, it was 
suggested that APOL1 status should be used for potential live kidney donors. However, this 
association had not been established in 2006, so no such screening was performed in the 
present case at the time of transplant. Our recipient exhibited an early FSGS recurrence 
leading to ESRD only five years after transplantation. This outcome is in agreement with the 
Kaplan-Meier kidney allograft survival observed in the study from Reeves-Daniel: only 50% 
of grafts survived at 5 years in the cohort of patients carrying the same haplotype11 . 
Another major issue is the risk of the donor developing accelerated kidney disease 
after donation. Can kidney disease related to APOL1 polymorphisms be triggered or 
accelerated by kidney donation? Surprisingly, there is currently no data available relative to 
clinical outcome in living relative donors carrying APOL1 polymorphisms. Based on the logic 
that close relatives of African-American ESRD patients with APOL1-related kidney failure 
are likely to share one or more APOL1 risk alleles, Cohen et al proposed a screening 
programme for self-identified, potential, African-American live donors14. In our case, the 
donor exhibited a marked decline in kidney function and significant proteinuria 5 years after 
donation without risk factor for developing post-donation kidney failure at the time of 
transplantation except donor origin. Linkage of the Organ Procurement and Transplantation 
Network registry data to administrative billing revealed that with a mean time from donation 
to end of follow-up of 7.7 years, diagnosed CKD after donation was approximately twice as 
frequent among donors of African descent than those of Caucasian descent15. The contribution 
of APOL1 polymorphism to this worse clinical outcome remains to be determined. 
The mechanisms by which APOL1 polymorphisms are associated with FSGS are not 
known. The APOL1 risk alleles are still only risk factors for vascular related  ESRD and 
FSGS in African American patients but a direct relationships between the genetic event and 
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the pathological process leading to the kidney disease remains to be determined. Possibly, the 
variable clinical and histological patterns of kidney disease are related to a “two hits” event: 
firstly a donor related genetic variant and a second hit, which may be viral, metabolic or 
environmental16. It is plausible that nephronic reduction and hyperfiltration related to kidney 
donation constituted such a second hit in our case.  
Our observation is also unusual in that the donor and recipient are monozygotic twin 
brothers. This is a particularly suitable context for analysing the APOL1-related 
phenotype/genotype relationship. At the time of donation, the recipient exhibited ESRD with 
significant proteinuria and hypertension and the donor’s kidney function and blood pressure 
were considered to be normal. The recipient exhibited an early recurrence of FSGS and donor 
displayed decreased eGFR with mild proteinuria five years post-transplant donation. These 
different outcomes illustrate the well-known concept of phenotypic discordance between 
monozygotic twins which might be related to environmental differences but also to epigenetic 
modifications of histones and DNA17 such as DNA methylation profiles18.  
Finally, we describe the first case of chronic kidney disease in both monozygotic twins 
carrying APOL1 polymorphism after kidney donation that is known to be a risk factor to graft 
loss. The mechanisms involved in kidney disease after donation required further experimental 
and human genetic studies.  
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Figure legends  
 
Figure 1 Kidney graft biopsy showing typical FSGS lesions, fibrosis and tubular atrophy 
Figure 1A: Presence of a small lymphocytic infiltrate in an area of fibrosis. Fibrosis and 
tubular atrophy. Note the presence of one glomerulus with apparently normal morphology 
(Periodic acid-Schiff x 20) 
Figure 1B: FSGS lesion at the vascular pole of the glomerulus (Periodic acid-Schiff x20) 
 
 
Figure 2 Evolution of eGFR and Proteinuria before and after transplantation for both 
donor and recipient. 
eGFR is expressed in ml/min/1.73 m² according to the 6-variable MDRD formula and 
proteinuria in g/day. 
B1, B2, B3: Graft biopsy 1, 2 and 3. D1, D2: Dialysis period for recipient. T: Transplantation. 
Yn: n years post transplantation 
 
Figure 3 Chromatograms of exon 7 of the APOL1 gene, showing sequences of variants 
identified as heterozygous composite G1/G2. 
The twins express both at-risk alleles: G1 (consisting of variants derived from rs73885319 
and rs60910145) that encodes a protein with two nonsynonymous amino acid substitutions, 
and G2 (rs71785313) that encodes a protein with a deletion of two amino acids from the same 
C terminal domain of APOL1. 
Arrows indicate the position of the mutations. 
 
 
 
 
 
 
 
 
 
